|
Personal Data: Name: Shu-Pin Huang M.D.& Ph.D. Address: Department of Urology, Kaohsiung Medical University No. 100, Shih-Chuan 1st Road , Kaohsiung, TAIWAN 807 Marital Status: Married Birth Year: 1972 Place of Birth: Kaohsiung, Taiwan |
|
Current Position: Professor and Visiting Staff
Department of Urology, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, TAIWAN 807
Phone: 886-7-3121101 ext. 6694
Fax: 886-7-3211033
E-mail: shpihu73@gmail.com; shpihu@yahoo.com.tw
Education:
1. School of Medicine, Kaohsiung Medical University (KMU), 1990-1997 (M.D. Degree)
2. Graduate Institute of Medicine, Kaohsiung Medical University (KMU) 1999~2004 (Ph.D. Degree)
Post-Graduate Training:
1. Resident , Dept. of Urology, KMU 1997-1999
2. Chief Resident, Dept. of Urology, KMU, 2000
3. Visiting Staff, Dept. of Urology, KMU, 2000 ~ present
Postdoctoral Research
George Whipple Lab for Cancer Research, University of Rochester Medical Center, NY, USA, 2005~2006
Professional Society Membership:
1. Member of Taiwan Urological Association (TUA)
2. Member of American Urological Association (AUA)
3. Member of European Association of Urology (EAU)
4. Member of Urological Association of Asia (UAA)
Role of PI in Clinical Trials:
|
Protocol Name and Number: Role: PI |
Study Period |
|
Protocol number.: 212082PCR3001 An Open-Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy. |
2012.09.01~2014.12.31 |
|
Protocol Number: MDV3100-14 PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. |
2013.11.01~2018.11.01 |
|
Protocol Number: ARI 114265 A randomized, double-blind, parallel group study to compare the efficacy and safety of combination treatment with dutasteride (0.5mg) and tamsulosin(0.2mg) with tamsulosin(0.2mg) monotherapy, administered once daily for 2years, on the improvement of symptoms and health outcomes in men with moderate to severe benign prostatic hyperplasia. |
2014.01.01~2017.12.31 |
|
Protocol Number: 9785-CL-0232 Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy |
2014.05.01~2017.03.31 |
|
Protocol Number: 9785-CL-0403 A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure (UPWARD) |
2014-7-30~2018-06-30 |
|
Protocol Number: ONC-MA-1001 A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis |
2015~ |
|
Protocol Number: Orion Pharma Protocol: 3104007 A Multinational, Randomized, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High- Risk Non-Metastatic Castration-Resistant Prostate Cancer |
2015~ |
|
Protocol Number: MDV3100-13 A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy |
2016~ |
|
Bayer ARASENS 17777 study A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer |
2017~ |
|
Protocol Number: MVT-601-3201 HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer |
2017~ |
|
Protocol Number: 9785-CL-0335 ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) |
2017~ |
|
Protocol Number: CO39303 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TESTING IPATASERIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER |
2017~ 2018 |
Biography;
Prof/Dr. Shu-Pin Huang has received his PhD in Graduate of Medicine, Kaohsiung Medical University during the period of 1999 to 2004. Currently, he is working as Professor and Visiting Staff in Department of Urology, Kaohsiung Medical University Hospital & Kaohsiung Medical University in Taiwan. He is serving as a reviewer of several reputed journals like New England Journal of Medicine, Clinical Cancer Research, PLOS One, Cancer, Clinica Chimic Acta, Annals of Surgical Oncology, Journal of Endourology, International Journal of Oncology, Medicine, J Endourology, … etc. Prof Huang has published over 140 research articles in peer-review SCI journals. He is a member of Urological Association of Taiwan, American Urological Association (AUA) and European Association of Urology (EAU) and also served as Academic Editor for Medicine and Member of Editorial Board of International Journal of Urology. In additional to general Urology, Renal Transplantation and Robotic Surgery in Urology Oncology (majority on radical prostatectomy and Uro-oncology), Dr. Huang’s research interests were mainly focus on: Prostate Cancer, Molecular Epidemiology, Pharmacogenomic studies, Metabolic syndrome, Endocrine-Related Cancer, Urolithiasis, Andrology, Male Erectile dysfunction … etc.
Selected Published Papers:
1. Huang CH, Wang SC, Chen IC, Chen YT, Liu PL, Fang SH, Huang SP, Yeh HC, Liu CC, Lee PY, Lin TC, Cheng WC, Su CC, Wu HE, Chen YR, Li CY. (2021, Jun). Protective Effect of Piplartine against LPS-Induced Sepsis through Attenuating the MAPKs/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation. Pharmaceuticals (Basel), Jun 18;14(6):588. .
2. Huang SP, Chen LC, Chen YT, Lee CH, Huang CY, Yu CC, Lin VC, Lu TL, Bao BY. (2021, Jun). PTBP1 Genetic Variants Affect the Clinical Response to Androgen-deprivation Therapy in Patients With Prostate Cancer. Cancer Genomics Proteomics., 18(3):325-334.. 本人為第一作者.
3. Tsai YC, Huang CY, Hsueh YM, Fan YC, Fong YC, Huang SP, Geng JH, Chen LC, Lu TL, Bao BY. (2021, Jun). Genetic variants in MAPK10 modify renal cell carcinoma susceptibility and clinical outcomes. Life sciences, 275:119396.
4. Huang SP, Chen YT, Chen LC, Lee CH, Huang CY, Yu CC, Lin VC, Lu TL, Bao BY. (2021, May). NRG1 Genetic Variant Influences the Efficacy of Androgen- Deprivation Therapy in Men with Prostate Cancer. Biomedicines, 9(5):528. 本人為第一作者.
5. Su CC, Wang SC, Chen IC, Chiu FY, Liu PL, Huang CH, Huang KH, Fang SH, Cheng WC, Huang SP, Yeh HC, Liu CC, Lee PY, Huang MY, Li CY. (2021, May). Zerumbone Suppresses the LPS-Induced Inflammatory Response and Represses Activation of the NLRP3 Inflammasome in Macrophages. Front Pharmacol. , 12:652860.
6. Wang SH, Huang SP, Pan YJ, Hsiao PC, Li CY, Chen LC, Yu CC, Huang CY, Lin VC, Lu TL, Bao BY. (2021, May). Association between the polygenic liabilities for prostate cancer and breast cancer with biochemical recurrence after radical prostatectomy for localized prostate cancer. Am J Cancer Res, 11(5):2331-2342.
7. Lin TY, Tsai MC, Tu W, Yeh HC, Wang SC, Huang SP, Li CY. (2021, Feb). Role of the NLRP3 Inflammasome: Insights Into Cancer Hallmarks. Frontiers in Immunology, Feb 3;11:610492.. 本人為通訊作者.
8. Liu CC, Huang SP, Hsieh TJ, Lee CH, Cheng KH, Huang TY, Geng JH, Li CC, Wu WJ, Lee YC. (2021, Feb). Fatty liver index is associated with the risk of testosterone deficiency in aging men without metabolic syndrome. Andrology, 9(3):863-872. .
9. Huang CY, Huang SP, Hsueh YM, Chen LC, Lu TL, Bao BY. (2020, Nov). Genetic Analysis Identifies the Role of HLF in Renal Cell Carcinoma. Cancer Genomics Proteomics., 17(6):827-833..
10. Li CC, Chien TM, Huang SP, Yeh HC, Lee HY, Ke HL, Wen SC, Chang WC, Juan YS, Chou YH, Wu WJ. (2020, Nov). Single-Site Sutureless Partial Nephrectomy for Small Exophytic Renal Tumors. J Clin Med., 9(11):3658..
11. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators (2020, Sep). Nonmetastatic, Castration- Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med, 383(11):1040-1049..
12. Liu CC, Hsieh TJ, Wu CF, Lee CH, Tsai YC, Huang TY, Wen SC, Lee CH, Chien TM, Lee YC, Huang SP, Li CC, Chou YH, Wu WJ, Wu MT. (2020, Sep). Interrelationship of environmental melamine exposure, biomarkers of oxidative stress and early kidney injury. J Hazard Mater., 396:122726.
13. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. (2020, Jun). Oral Relugolix for Androgen- Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. , 382(23):2187-2196.
14. Ke CC, Chen LC, Yu CC, Cheng WC, Huang CY, Lin VC, Lu TL, Huang SP, Bao BY. (2020, May). Genetic Analysis Reveals a Significant Contribution of CES1 to Prostate Cancer Progression in Taiwanese Men. Cancers (Basel)., ; 12(5):1346 . 本人為通訊作者.
15. Yu CC, Chen LC, Huang CY, Lin VC, Lu TL, Lee CH, Huang SP, Bao BY. (2020, Apr). Genetic association analysis identifies a role for ANO5 in prostate cancer progression. Cancer Med., 9(7):2372-2378. 本人為通訊作者.
16. Yu CC, Chen LC, Lin WH, Lin VC, Huang CY, Lu TL, Lee CH, Huang SP, Bao BY. (2020, Mar). Genetic Association Analysis of Cell Cycle Regulators Reveals YWHAZ Has Prognostic Significance in Prostate Cancer. Cancer Genomics Proteomics. , 17(2):209-216. 本人為通訊作者.
17. Lee CH, Chen LC, Yu CC, Lin WH, Lin VC, Huang CY, Lu TL, Huang SP, Bao BY. (2019, Nov). Prognostic Value of CD1B in Localised Prostate Cancer.. International Journal of Environment Research and Public Health, 16(23). pii: E4723. 本人為通訊作者.
18. Yu CC, Chen LC, Lin VC, Huang CY, Cheng WC, Hsieh AR, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY. (2019, Jun). Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy.. Cancer Medicine, 8(6): 2777–2783. 本人為通訊作者.
19. Su CC, Hsieh KL, Liu PL, Yeh HC, Huang SP, Fang SH, Cheng WC, Huang KH, Chiu FY, Lin IL, Huang MY, Li CY (2019, Apr). AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.. International Journal of Molecular Sciences, 20(7): 1647.
20. Yu CC, Chen LC, Chiou CY, Chang YJ, Lin VC, Huang CY, Lin IL, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY. (2019, Apr). Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression. Cancer Cell International, 19: 87. 本人為通訊作者.
21. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR1; ARAMIS Investigators. (2019, Mar). Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.. The New England Journal of Medicine, 380(13):1235-1246..
22. Huang CY, Hsueh YM, Chen LC, Cheng WC, Yu CC, Chen WJ, Lu TL, Lan KJ, Lee CH, Huang SP, Bao BY (2018, Nov). Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival. Cancer Medicine, 7(12): 6104–6111. 本人為通訊作者.
23. Liu CC, Lee YC, Huang SP, Cheng KH, Hsieh TJ, Huang TY, Lee CH, Geng JH, Li CC, Wu WJ. (2018, Nov). Hepatocyte Nuclear Factor-4α P2 Promoter Variants Are Associated With the Risk of Metabolic Syndrome and Testosterone Deficiency in Aging Taiwanese Men.. Journal of Sexual Medicine, 15(11): 1527- 1536.
24. Chen YC, Chen HW, Lee CH, Huang SP. (2018, Oct). A Rare Delayed Bladder Migration of a Hem-o-lok Clip 5 Years after Robotic-Assisted Radical Prostatectomy.. Urologia Internationalis, 19:1-3. 本人為通訊作者.
25. Pai VC, Hsu CC, Chan TS, Liao WY, Chuu CP, Chen WY, Li CR, Lin CY, Huang SP, Chen LT, Tsai KK. (2018, Sep). ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling. Oncogene, 38(8):1340-1353.
26. Chen YC, Chen HW, Huang SP, Yeh HC, Li CC. (2018, Aug). Adequate rectal preparation reduces hospital admission for urosepsis after transrectal ultrasound - guided prostate biopsy.. International Braz J Urol , 5;44.
27. Huang EY, Chang YJ, Huang SP, Lin VC, Yu CC, Huang CY, Yin HL, Chang TY, Lu TL, Bao BY. (2018, Jul). A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer. Journal of Cellular and Molecular medicine, 22(7); 3661-3670. 本人為第一作者.
28. Liu CC, Hsieh TJ, Wu CF, Tsai YC, Huang SP, Lee YC, Huang TY, Shen JT, Chou YH, Huang CN, Wu WJ, Wu MT. (2017, Dec). Urinary melamine excretion and increased markers of renal tubular injury in patients with calcium urolithiasis: A cross-sectional study.. Environmental Pollution, 231(Pt 2):1284- 1290.
29. Cha TL, Wu TT, Vogelzang NJ, Huang CY, Huang SP, Lin CC, Ou YC, Pang ST, Shen DH, Wu WJ, Chang WY. (2017, Nov). Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. Journal of the Formosan Medical Association, 116(11):825-836.
30. Lin VC, Huang SP, Huang CY, Yu CC, Yin HL, Huang TY, Lee CH, Lu TL, Bao BY. (2017, Sep). Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer.. International Journal of Medical Sciences, 14(12):1301-1306.
31. Lin YC, Hour TC, Tsai YC, Huang SP, Wu WJ, Chen CH, Pu YS, Chung SD, Huang CY. (2017, Sep). Preliminary evidence of polymorphisms of cell cycle regulatory genes and their roles in urinary tract urothelial cancer susceptibility and prognosis in a Taiwan population.. Urologic Oncology, 35(9):543.e7- 543.e16.
32. Liu CC, Huang SP, Cheng KH, Hsieh TJ, Huang CN, Wang CJ, Yeh HC, Tsai CC, Bao BY, Wu WJ, Lee YC. (2017, Jun). Lower SHBG level is associated with higher leptin and lower adiponectin levels as well as metabolic syndrome, independent of testosterone.. Scientific Reports, 35(9):543.e7-543.e16.
33. Lin VC, Huang SP, Ting HJ, Ma WL, Yu CC, Huang CY, Yin HL, Huang TY, Lee CH, Chang TY, Lu TL, Bao BY. (2017, May). Vitamin D receptor-binding site variants affect prostate cancer progression.. Oncotarget, 8(43):74119-74128.
34. Lee YC, Huang SP, Tsai CC, Cheng KH, Juan YS, Wu WJ, Bao BY, Huang CN, Wang CJ, Liu CC. (2017, Apr). Associations of VEGF Gene Polymorphisms With Erectile Dysfunction and Related Risk Factors.. Journal of Sexual Medicine, 14(4):510-517.
35. Geng JH, Lin VC, Yu CC, Huang CY, Yin HL, Chang TY, Lu TL, Huang SP, Bao BY. (2016, Nov). Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.. International Journal of Molecular Sciences , 17(12):1970. 本人為通訊作者.
36. Lin VC, Lu TL, Yin HL, Yang SF, Lee YC, Liu CC, Huang CY, Yu CC, Chang TY, Huang SP, Bao BY. (2016, Nov). Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate Cancer. International Journal of Molecular Sciences, 17(12):1996. . 本人為通訊作者.
37. Lee YC, Huang SP, Juan YS, Huang TY, Liu CC. (2016, Sep). Impact of metabolic syndrome and its components on kidney stone in aging Taiwanese males.. The Aging Male, 19(3):197-201.
38. Chien TM, Lu YM, Geng JH, Huang TY, Ke HL, Huang CN, Li CC, Chou YH, Wu WJ, Huang SP. (2016, Aug). Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients. Asian Pacific Journal of Cancer Prevention, , 17(3):1187-91. 本人為通訊作者.
39. Lee CH, Pao JB, Lu TL, Lee HZ, Lee YC, Liu CC, Huang CY, Lin VC, Yu CC, Yin HL, Huang SP, Bao BY. (2016, Aug). Prognostic Value of Prostaglandin- endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical Prostatectomy. International Journal of Medical Sciences, 13(9):696- 700. 本人為通訊作者.
40. Lee YC, Juan YS, Liu CC, Bao BY, Wang CJ, Wu WJ, Huang CN, Huang SP. (2016, Aug). The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms. BJU International, 118(2):313-9.. 本人為通訊作者.
41. Yeh HC, Chien TM, Wu WJ, Li CC, Li WM, Ke HL, Chou YH, Wang CJ, Huang SP, Li CF, Liang PI, Huang CN. (2016, Aug). Is preoperative anemia a risk factor for upper tract urothelial carcinoma following radical nephroureterectomy? Urologic Oncology.34(8):337.e1-9.
42. Tai SY, Huang SP, Bao BY, Wu MT. (2016, Jul). Urinary melatonin- sulfate/cortisol ratio and the presence of prostate cancer: A case-control study.. Scientific Reports, 6:29606.
43. Tai SY, Hsieh HM, Huang SP, Wu MT. (2016, Mar). Hair dye use, regular exercise, and the risk and prognosis of prostate cancer: multicenter case-control and case-only studies. BMC Cancer. 16:242.本人為通訊作者.
44. Bao BY, Lin VC, Yu CC, Yin HL, Chang TY, Lu TL, Lee HZ, Pao JB, Huang CY, Huang SP. (2016, Feb). Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival.. Scientific Reports. 6:22124. 本人為通訊作者.
45. Yang SM, Huang CY, Shiue HS, Huang SP, Pu YS, Chen WJ, Lin YC, Hsueh YM. (2015, Dec). Joint Effect of Urinary Total Arsenic Level and VEGF-A Genetic Polymorphisms on the Recurrence of Renal Cell Carcinoma.. PLOS ONE, 10(12):e0145410.
46. Geng JH, Huang SP, Huang CY. (2015, Oct). Prognostic factors in Taiwanese patients with penile-invasive squamous cell carcinoma.. Kaohsiung Journal of Medical Sciences , 31(10):523-8..
47. Yeh HC, Jan HC, Wu WJ, Li CC, Li WM, Ke HL, Huang SP, Liu CC, Lee YC, Yang SF, Liang PI, Huang CN. (2015, Oct). Concurrent Preoperative Presence of Hydronephrosis and Flank Pain Independently Predicts Worse Outcome of Upper Tract Urothelial Carcinoma.. PLOS ONE, 10(10):e0139624.
48. Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Lu TL, Chiang HC, Bao BY. (2015, Sep). Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer.. Scientific Reports, 5:14045.
49. Liu CC, Hsieh HM, Wu CF, Hsieh TJ, Huang SP, Chou YH, Huang CN, Wu WJ, Wu MT. (2015, Apr). Long-term prescription of α-blockers decrease the risk of recurrent urolithiasis needed for surgical intervention-a nationwide population- based study. PLOS One, 10(4):e0122494.
50. Chen CS, Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Bao BY. (2015, Feb). Genetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer.. Int J Med Sci., 12(3):243-7.
51. Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Juang SH, Bao BY. (2015, Feb). Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer. Scientific Reports. 5:8556.
52. Cheng KH, Hsi E, Liu CC, Huang CN, Lee YC, Chu CS, Bao BY, Chang CF, Huang SP, Kuo PL, Lai WT. (2015, Jan). The Associations of Novel Vitamin D3 Metabolic Gene CYP27A1 Polymorphism, Adiponectin/Leptin Ratio, and Metabolic Syndrome in Middle-Aged Taiwanese Males. International Journal of Endocrinology, 2015:658151.
53. Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY. (2014, Dec). Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer, 135(11):2661-7. NSC 100-2314-B-039-009-MY3. 本人為第一作者.
54. Lee HY, Wu WJ, Huang CH, Chou YH, Huang CN, Lee YC, Yang KF, Lee MH, Huang SP. (2014, Aug). Clinical predictor of survival following docetaxel-based chemotherapy. Oncol Lett. , 8(4):1788-1792. 本人為通訊作者.
55. Hour TC, Chung SD, Kang WY, Lin YC, Chuang SJ, Huang AM, Wu WJ, Huang SP, Huang CY, Pu YS. (2014, Jun). EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol, 89(4):591-605.
56. Huang TY, Lin JP, Huang SP. (2014, Apr). Medullary sponge kidney on retrograde pyelography. Chonnam Med J., 50(1):21-2. 本人為通訊作者.
57. Lin VC1, Huang CY, Lee YC, Yu CC, Chang TY, Lu TL, Huang SP, Bao BY. (2014, Apr). Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients. Arch Toxicol., 88(4):901-11. NSC 100- 2314-B-039-009-MY3. 本人為通訊作者.
58. Yu CC, Lin VC, Huang CY, Liu CC, Wang JS, Wu TT, Pu YS, Huang CH, Huang CN, Huang SP*, Bao BY*. (2013, Dec). Prognostic Significance of Cyclin D1 Polymorphisms on Prostate-Specific Antigen Recurrence After Radical Prostatectomy. Ann Surg Oncol. , 20 Suppl 3:492-9. 本人為通訊作者.
59. Huang SP, Lin VC, Lee YC, Yu CC, Huang CY, Chang TY, Lee HZ, Juang SH, Lu TL, Bao BY. (2013, Nov). Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients. . Eur J Cancer., 49(17):3729-37.NSC 99-2314-B-037-018-MY3. 本人為第一作者.
60. Huang TY1, Lin JP, Lieu AS, Chen YT, Chen HS, Jang MY, Shen JT, Wu WJ, Huang SP, Juan YS. (2013, Oct). Pituitary apoplexy induced by Gonadotropin- releasing hormone agonists for treating prostate cancer-report of first Asian case. World J Surg Oncol., 11:254.
61. Cheng KH, Huang SP, Huang CN, Lee YC, Chu CS, Chang CF, Lai WT, Liu CC. (2013, Mar). The impact of estradiol and 1,25(OH)2D3 on metabolic syndrome in middle-aged Taiwanese males. PLoS One., 8(3):e60295.
62. Chang CF, Pao JB, Yu CC, Huang CY, Huang SP, Yang YP, Huang CN, Chang TY, You BJ, Lee HZ, Hour TC, Bao BY. (2013, Feb). Common Variants in IGF1 Pathway Genes and Clinical Outcomes After Radical Prostatectomy. Ann Surg Oncol., 20(7):2446-52.
63. Yu CC, Huang SP, Lee YC, Huang CY, Liu CC, Hour TC, Huang CN, You BJ, Chang TY, Huang CH, Bao BY. (2013, Jan). Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PLoS One., 8(1):e54627.